Self-Monitoring of Blood Glucose in Type 2 Diabetes

Kennedy, Laurence

doi:10.2337/diacare.24.6.977

Cited by 38 publications

(25 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The conclusion of this Counterpoint, that SMBG in type 2 diabetic patients not receiving insulin is ineffective in lowering A1C levels, is consistent with the conclusions of several reviews (24,25) and a meta-analysis (26). A meta-analysis in a third review appearing in this issue of Diabetes Care (27) found a small (Ϫ0.39%), but statistically significant, decrease in A1C levels in patients performing SMBG compared with control groups.…”

supporting

confidence: 83%

Counterpoint: Self-Monitoring of Blood Glucose in Type 2 Diabetic Patients not Receiving Insulin

Davidson

2005

Diabetes Care

102

View full text Add to dashboard Cite

supporting

confidence: 83%

Counterpoint: Self-Monitoring of Blood Glucose in Type 2 Diabetic Patients not Receiving Insulin

Davidson

2005

Diabetes Care

102

View full text Add to dashboard Cite

“…Prior to 2001, data supporting the use of SMBG in non-insulin-treated type 2 diabetes were limited, in spite of increasing SMBG use, leading to repeated calls for more studies in this patient group. 35,36 However, until recently, the majority of randomized controlled trials (nine out of 14 performed up to the year 2010) failed to show any significant benefit on metabolic control [37][38][39] (for reviews, see Davidson 11 and Kolb et al…”

Section: What Do the Guidelines Say On Smbg In Diabetes?mentioning

confidence: 99%

Self-Monitoring of Blood Glucose in Diabetes: From Evidence to Clinical Reality in Central and Eastern Europe—Recommendations from the International Central-Eastern European Expert Group

Czupryniak

Barkai

Bolgarska³

et al. 2014

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Self-monitoring of blood glucose (SMBG) is universally considered to be an integral part of type 1 diabetes management and crucial for optimizing the safety and efficacy of complex insulin regimens. This extends to type 2 diabetes patients on intensive insulin therapy, and there is also a growing body of evidence suggesting that structured SMBG is beneficial for all type 2 diabetes patients, regardless of therapy. However, access to SMBG can be limited in many countries in Central and Eastern Europe. A consensus group of diabetes experts from 10 countries in this region (with overlapping historical, political, and social environments)-Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia, Slovenia, and Ukraine-was formed to discuss the role of SMBG across the spectrum of patients with diabetes. The group considered SMBG to be an essential tool that should be accessible to all patients with diabetes, including those with non-insulin-treated type 2 diabetes. The current article summarizes the evidence put forward by the consensus group and provides their recommendations for the appropriate use of SMBG as part of individualized patient management. The ultimate goal of these evidence-based recommendations is to help patients and providers in Central and Eastern Europe to make optimal use of SMBG in order to maximize the efficacy and safety of glucose-lowering therapies, to prevent complications, and to empower the patient to play a more active role in the management of their diabetes.

show abstract

“…T he value of self-monitored blood glucose (SMBG) testing in type 2 diabetes is controversial (1)(2)(3). Results from observational studies of SMBG have been inconsistent (4 -13).…”

mentioning

confidence: 99%

Intensified Blood Glucose Monitoring Improves Glycemic Control in Stable, Insulin-Treated Veterans With Type 2 Diabetes

et al. 2003

View full text Add to dashboard Cite

OBJECTIVE -To examine the effect of intensified self-monitored blood glucose (SMBG) testing on glycemic control. RESEARCH DESIGN AND METHODS-Subjects with stable, insulin-treated type 2 diabetes performed SMBG using an electronic blood glucose meter before all meals and at bedtime for 8 weeks. Baseline data were collected on demographics, clinical characteristics, diet, and exercise. HbA 1c was measured at baseline, at 4 weeks, and at 8 weeks. After the intensified monitoring period, subjects resumed their usual monitoring. HbA 1c was then measured at 24, 37, and 52 weeks. Multivariate linear regression was used to determine the effect of monitoring on glycemic control.RESULTS -A total of 201 subjects completed the monitoring period. The baseline HbA 1c (8.10 Ϯ 1.67%) decreased during the monitoring period by 0.30 Ϯ 0.68% (P Ͻ 0.001) at 4 weeks and by 0.36 Ϯ 0.88% (P Ͻ 0.001) at 8 weeks. Although entry HbA 1c and compliance independently predicted the week 8 HbA 1c (r ϭ 0.862, P Ͻ 0.001), standardized regression analysis found that compliance with the SMBG protocol influenced the week 8 HbA 1c more than age, sex, BMI, exercise level, carbohydrate consumption, or treatment intensity at baseline. However, SMBG benefited only subjects whose testing compliance exceeded 75% or with an entry HbA 1c Ͼ8.0%. Decreases in HbA 1c (Ϫ0.31 Ϯ 1.17%, P ϭ 0.001) persisted in the 159 subjects followed for 52 weeks.CONCLUSIONS -Intensified blood glucose monitoring improved glycemic control in a large cohort of stable, insulin-treated veterans with type 2 diabetes. SMBG provided a strong stimulus for improved self-care resulting in clinically important and sustained reductions in HbA 1c .

show abstract

Self-Monitoring of Blood Glucose in Type 2 Diabetes

Cited by 38 publications

References 11 publications

Counterpoint: Self-Monitoring of Blood Glucose in Type 2 Diabetic Patients not Receiving Insulin

Counterpoint: Self-Monitoring of Blood Glucose in Type 2 Diabetic Patients not Receiving Insulin

Self-Monitoring of Blood Glucose in Diabetes: From Evidence to Clinical Reality in Central and Eastern Europe—Recommendations from the International Central-Eastern European Expert Group

Intensified Blood Glucose Monitoring Improves Glycemic Control in Stable, Insulin-Treated Veterans With Type 2 Diabetes

Contact Info

Product

Resources

About